Asunto(s)
Continuidad de la Atención al Paciente/organización & administración , Atención a la Salud/organización & administración , Trastornos Relacionados con Sustancias/rehabilitación , Continuidad de la Atención al Paciente/normas , Atención a la Salud/normas , Humanos , Centros de Tratamiento de Abuso de Sustancias/organización & administraciónRESUMEN
BACKGROUND: Psychostimulant treatment may improve simulated driving performance in young adults with attention-deficit/hyperactivity disorder (ADHD). METHOD: This was a randomized, double-blind, placebo-controlled, crossover study of simulated driving performance with mixed amphetamine salts-extended release (MAS XR) 50 mg/day (Cohort 1) and atomoxetine 80 mg/day (Cohort 2) in young adults with ADHD. RESULTS: Adults aged 19 to 25 years with AD/HD (N = 19) who were administered MAS XR significantly improved overall simulated driving performance versus placebo up to 12 hours after dosing. In contrast, there were no statistically significant differences in simulated-driving-performance scores between atomoxetine and placebo. At endpoint, MAS XR reduced ADHD Rating Scale scores > or = 30% in 80% of subjects, whereas atomoxetine achieved this level of improvement for 40%. LIMITATIONS: Small sample size and use of simulated driving may limit generalizability of the findings. CONCLUSION: MAS XR in young adults with ADHD yields significant improvements in simulated driving performance and ADHD symptoms.
Asunto(s)
Inhibidores de Captación Adrenérgica/uso terapéutico , Anfetamina/uso terapéutico , Trastorno por Déficit de Atención con Hiperactividad/tratamiento farmacológico , Trastorno por Déficit de Atención con Hiperactividad/epidemiología , Conducción de Automóvil/estadística & datos numéricos , Estimulantes del Sistema Nervioso Central/uso terapéutico , Simulación por Computador , Propilaminas/uso terapéutico , Adulto , Clorhidrato de Atomoxetina , Preparaciones de Acción Retardada , Esquema de Medicación , Femenino , Humanos , Masculino , Proyectos Piloto , Adulto JovenRESUMEN
The author explores the FAA Medical Standards, including old and new approaches toward rehabilitation; special issuance; and pilot initiatives. The current treatment model is also seen in various impaired physician programs around the U.S.